

# CRISPR-Cas based diagnostic assay for *Mycobacterium tuberculosis*


**Domain:** Diagnostic (Assay/Kit)

**About Technology:** The present invention in general relates to assays and methods for the identification of Tuberculosis diseases. Particularly, the present invention relates to an in-vitro assay for the identification of *Mycobacterium tuberculosis* based on the CRISPR-Cas13a system

**Intended Use:** Detect *Mycobacterium tuberculosis* infections

## Advantages:

- Rapid & Isothermal: Results in <3hour without thermal cycler
- Highly Specific & Sensitive: RNA-guided CRISPR detection
- Compatible with fluorescence or lateral flow readouts
- Potential for point-of-care use



**IP Status:** Filed (Indian Patent Application No.- 202311071943)

**Technology Transfer Status:** Transferred to a company on non-exclusive basis

**Development Status:** Third party validation complete

**Institute(s):** ICMR-National Institute for Research in Tuberculosis (NIRT)

**Inventor(s):** Dr.K.R.Uma Dev, P.Venkatesan

For Licensing Opportunities contact: [patentmitra.hq@icmr.gov.in](mailto:patentmitra.hq@icmr.gov.in)